EQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need...

Stats
Today's Volume	80 121.00
Average Volume	367 004
Market Cap	60.29M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.170 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.50
ATR14	$0.0230 (1.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Tom Penny	Sell	0	Common Stock
2024-03-06	Tom Penny	Sell	45 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	60 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)

INSIDER POWER
61.76
Last 97 transactions
Buy: 3 858 069 \| Sell: 577 250

Volume Correlation

Long: 0.01 (neutral)

Short: 0.79 (moderate)

Signal:(46.106) Neutral

Equillium Inc Correlation

10 Most Positive Correlations
GRNV	0.919
EGRX	0.917
AXTI	0.917
VVOS	0.915
FVE	0.909
BCRX	0.906
NVEE	0.904
OTRK	0.903
BFRI	0.903
CNSP	0.898

10 Most Negative Correlations
AMRB	-0.94
LSTR	-0.939
RMBS	-0.937
LSCC	-0.936
MCHP	-0.932
KE	-0.93
SNSR	-0.926
SMH	-0.923
SOXX	-0.918
GRID	-0.917

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Equillium Inc Correlation - Currency/Commodity

0.29
( neutral )

0.00
( neutral )

0.51
( weak )

0.00
( neutral )

-0.14
( neutral )

Equillium Inc Financials

Annual	2023
Revenue:	$36.08M
Gross Profit:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2023
Revenue:	$36.08M
Gross Profit:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2022
Revenue:	$15.76M
Gross Profit:	$15.64M (99.25 %)
EPS:	$-3.19

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.579

Financial Reports:

No articles found.

Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.